Artemisinin combination therapy mass drug administration in a setting of low malaria endemicity: Programmatic coverage and adherence during an observational study in Zanzibar

Malaria Journal

Volumn 16, Issue 1, 2017, Pages

  Ali, Abdullah S ^a   Thawer, Narjis G ^b   Khatib, Bakar ^a   Amier, Haji H ^a   Shija, Joseph ^a   Msellem, Mwinyi ^a   Al Mafazy, Abdul Wahid ^a   Garimo, Issa A ^b   Mkali, Humphrey ^b   Ramsan, Mahdi M ^b   Kafuko, Jessica M ^c   Paxton, Lynn A ^d   Reithinger, Richard ^b   Ngondi, Jeremiah M ^b  

^a and Children   (Tanzania)

^b RTI INTERNATIONAL   (United States)

^c UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adherence; Artemisinin based combination therapy; Hotspots; Mass drug administration; Zanzibar

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; DIHYDROARTEMISININ PLUS PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; ATTITUDE TO HEALTH; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG ADMINISTRATION; ENDEMIC DISEASE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE CONCEPTS; HIGH RISK POPULATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALE; MASS DRUG ADMINISTRATION; MEDICATION COMPLIANCE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCHOOL CHILD; PROGRAMMATIC COVERAGE; SCHOOL CHILD; SEX DIFFERENCE; SEX RATIO; TANZANIA; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION; YOUNG ADULT; COMBINATION DRUG THERAPY; PARASITEMIA; UTILIZATION;

ANTIMALARIALS; ARTEMISININS; DRUG THERAPY, COMBINATION; HUMANS; MALARIA; MASS DRUG ADMINISTRATION; PARASITEMIA; TANZANIA; TREATMENT ADHERENCE AND COMPLIANCE;

EID: 85027419304     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-017-1982-x     Document Type: Article

References (32)

1. Bhattarai A, Ali AS, Kachur SP, Mårtensson A, Abbas AK, Khatib R, et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med. 2007;4:e309.
2. Aregawi MW, Ali AS, Al-mafazy A, Molteni F, Katikiti S, Warsame M, et al. Reductions in malaria and anaemia case and death burden at hospitals following scale-up of malaria control in Zanzibar, 1999-2008. Malar J. 2011;10:46.
3. Programme Zanzibar Malaria Control. Malaria elimination in Zanzibar: a feasibility assessment. Zanzibar: Zanzibar Malaria Control Programme; 2009.
4. Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), National Bureau of, Statistics (NBS), Office of the Chief Government Statistician (OCGS), and ICF International. Tanzania HIV/AIDS and Malaria Indicator Survey 2011-12. Dar es Salaam, Tanzania: TACAIDS, ZAC, NBS, OCGS, and ICF International; 2013. https://dhsprogram.com/pubs/pdf/AIS11/AIS11.pdf.
5. WHO, Global Malaria Programme. Disease surveillance for malaria elimination: an operational manual. Geneva: World Health Organization; 2012.
6. Zanzibar Malaria Control Programme, Ministry of Health and Social Welfare. Roll back malaria indicator survey, 2007: main report. Zanzibar: Zanzibar Malaria Control Programme; 2008.
7. Moonen B, Cohen JM, Snow RW, Slutsker L, Drakeley C, Smith DL, et al. Operational strategies to achieve and maintain malaria elimination. Lancet. 2010;376:1592-603.
8. Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken W, et al. Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med. 2012;9:e1001165.
9. Sturrock HJW, Hsiang MS, Cohen JM, Smith DL, Greenhouse B, Bousema T, et al. Targeting asymptomatic malaria infections: active surveillance in control and elimination. PLoS Med. 2013;10:e1001467.
10. malERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med. 2011;8:e1000402.
11. Cotter C, Sturrock HJW, Hsiang MS, Liu J, Phillips AA, Hwang J, et al. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet. 2013;382:900-11.
12. Bardají A, Bassat Q, Alonso PL, Menéndez C. Intermittent preventive treatment of malaria in pregnant women and infants: making best use of the available evidence. Expert Opin Pharmacother. 2012;13:1719-36.
13. Douglas NM, John GK, von Seidlein L, Anstey NM, Price RN. Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria. Adv Parasitol. 2012;80:271-300.
14. Newby G, Hwang J, Koita K, Chen I, Greenwood B, von Seidlein L, et al. Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg. 2015;93:125-34.
15. Okell LC, Griffin JT, Kleinschmidt I, Hollingsworth TD, Churcher TS, White MJ, et al. The Potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS ONE. 2011;6:e20179.
16. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J. Mass drug administration for malaria. Cochrane Database Syst Rev. 2013; CD008846.
17. Programme Zanzibar Malaria Control. MEEDS & MCN Quarterly report: Quarter 2, April to June 2013. Zanzibar: Zanzibar Malaria Control Programme; 2013.
18. ®: Dihydroartemisinin and Piperaquine Phosphate (40/320 mg). http://en.holleycotec.com/downloadsfront.do?method=picker&flag=all&id=23cef49d-81fe-4906-9abe-8ba22fa4af89&fileId=15&memstate=&v=0.zip. Accessed on 29 July 2017.
19. ®: A new generation of artemisinin combination. http://www.artequick.com/index.php/2-main-category/2-product. Accessed on 29 July 2017.
20. Dial NJ, Ceesay SJ, Gosling RD, D'Alessandro U, Baltzell KA. A qualitative study to assess community barriers to malaria mass drug administration trials in The Gambia. Malar J. 2014;13:47.
21. De Martin S, von Seidlein L, Deen JL, Pinder M, Walraven G, Greenwood B. Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Trop Med Int Health. 2001;6:442-8.
22. Kaneko A. A community-directed strategy for sustainable malaria elimination on islands: short-term MDA integrated with ITNs and robust surveillance. Acta Trop. 2010;114:177-83.
23. Roy RN, Sarkar AP, Misra R, Chakroborty A, Mondal TK, Bag K. Coverage and awareness of and compliance with mass drug administration for elimination of lymphatic filariasis in Burdwan District, West Bengal, India. J Health Popul Nutr. 2013;31:171-7.
24. Ghosh S, Kole S, Samanta A. Mass drug administration for elimination of lymphatic filariasis: recent experiences from a district of West Bengal. India. Trop Parasitol. 2013;3:67.
25. Bhullar N, Maikere J. Challenges in mass drug administration for treating lymphatic filariasis in Papua, Indonesia. Parasit Vectors. 2010;3:70.
26. Cantey PT, Rout J, Rao G, Williamson J, Fox LM. Increasing compliance with mass drug administration programs for lymphatic filariasis in India through education and lymphedema management programs. PLoS Negl Trop Dis. 2010;4:e728.
27. Njomo DW, Amuyunzu-Nyamongo M, Magambo JK, Njenga SM. The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS ONE. 2012;7:e48395.
28. Lemma H, Löfgren C, San Sebastian M. Adherence to a six-dose regimen of artemether-lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region,Ethiopia. Malar J. 2011;10:349.
29. Narain JP, Dash AP, Parnell B, Bhattacharya SK, Barua S, Bhatia R, et al. Elimination of neglected tropical diseases in the South-East Asia Region of the World Health Organization. Bull World Health Organ. 2010;88:206-10.
30. Dembélé M, Bamani S, Dembélé R, Traoré MO, Goita S, Traoré MN, et al. Implementing preventive chemotherapy through an integrated National Neglected Tropical Disease Control Program in Mali. PLoS Negl Trop Dis. 2012;6:e1574.
31. Lemoine JF, Desormeaux AM, Monestime F, Fayette CR, Desir L, Direny AN, et al. Controlling neglected tropical diseases (NTDs) in Haiti: implementation strategies and evidence of their success. PLoS Negl Trop Dis. 2016;10:e0004954.
32. Garfield RM, Vermund SH. Health education and community participation in mass drug administration for malaria in Nicaragua. Soc Sci Med. 1982;1986(22):869-77.